Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study.

Hendriksz CJ, Burton B, Fleming TR, Harmatz P, Hughes D, Jones SA, Lin SP, Mengel E, Scarpa M, Valayannopoulos V, Giugliani R; STRIVE Investigators, Slasor P, Lounsbury D, Dummer W.

J Inherit Metab Dis. 2014 Nov;37(6):979-90. doi: 10.1007/s10545-014-9715-6. Epub 2014 May 9.

2.

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III trial.

Tak PP, Mease PJ, Genovese MC, Kremer J, Haraoui B, Tanaka Y, Bingham CO 3rd, Ashrafzadeh A, Travers H, Safa-Leathers S, Kumar S, Dummer W.

Arthritis Rheum. 2012 Feb;64(2):360-70.

3.

Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial.

Stohl W, Gomez-Reino J, Olech E, Dudler J, Fleischmann RM, Zerbini CA, Ashrafzadeh A, Grzeschik S, Bieraugel R, Green J, Francom S, Dummer W.

Ann Rheum Dis. 2012 Aug;71(8):1289-96. doi: 10.1136/annrheumdis-2011-200706. Epub 2012 Feb 2.

4.

A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis.

Owczarczyk K, Lal P, Abbas AR, Wolslegel K, Holweg CT, Dummer W, Kelman A, Brunetta P, Lewin-Koh N, Sorani M, Leong D, Fielder P, Yocum D, Ho C, Ortmann W, Townsend MJ, Behrens TW.

Sci Transl Med. 2011 Sep 21;3(101):101ra92. doi: 10.1126/scitranslmed.3002432.

5.

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial.

Rigby W, Tony HP, Oelke K, Combe B, Laster A, von Muhlen CA, Fisheleva E, Martin C, Travers H, Dummer W.

Arthritis Rheum. 2012 Feb;64(2):350-9. doi: 10.1002/art.33317.

6.

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.

Genovese MC, Kaine JL, Lowenstein MB, Del Giudice J, Baldassare A, Schechtman J, Fudman E, Kohen M, Gujrathi S, Trapp RG, Sweiss NJ, Spaniolo G, Dummer W; ACTION Study Group.

Arthritis Rheum. 2008 Sep;58(9):2652-61. doi: 10.1002/art.23732.

7.

Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: results of a randomized, single blind study.

Krueger JG, Ochs HD, Patel P, Gilkerson E, Guttman-Yassky E, Dummer W.

J Invest Dermatol. 2008 Nov;128(11):2615-24. doi: 10.1038/jid.2008.98. Epub 2008 May 22.

8.

Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness.

Guttman-Yassky E, Vugmeyster Y, Lowes MA, Chamian F, Kikuchi T, Kagen M, Gilleaudeau P, Lee E, Hunte B, Howell K, Dummer W, Bodary SC, Krueger JG.

J Invest Dermatol. 2008 May;128(5):1182-91. doi: 10.1038/jid.2008.4. Epub 2008 Jan 31.

9.

Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series.

Lowes MA, Chamian F, Abello MV, Leonardi C, Dummer W, Papp K, Krueger JG.

BMC Dermatol. 2007 Feb 26;7:2.

10.

Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a).

Lowes MA, Chamian F, Abello MV, Fuentes-Duculan J, Lin SL, Nussbaum R, Novitskaya I, Carbonaro H, Cardinale I, Kikuchi T, Gilleaudeau P, Sullivan-Whalen M, Wittkowski KM, Papp K, Garovoy M, Dummer W, Steinman RM, Krueger JG.

Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19057-62.

11.

Lack of intrinsic CTLA-4 expression has minimal effect on regulation of antiviral T-cell immunity.

Homann D, Dummer W, Wolfe T, Rodrigo E, Theofilopoulos AN, Oldstone MB, von Herrath MG.

J Virol. 2006 Jan;80(1):270-80.

12.

Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis.

Vugmeyster Y, Beyer J, Howell K, Combs D, Fielder P, Yang J, Qureshi F, Sandlund B, Kawaguchi L, Dummer W, Lowman H, McKeever K.

J Immunother. 2005 May-Jun;28(3):212-9.

PMID:
15838377
13.

Gamma delta T cell homeostasis is controlled by IL-7 and IL-15 together with subset-specific factors.

Baccala R, Witherden D, Gonzalez-Quintial R, Dummer W, Surh CD, Havran WL, Theofilopoulos AN.

J Immunol. 2005 Apr 15;174(8):4606-12.

14.

Recent immune status determines the source of antigens that drive homeostatic T cell expansion.

Kieper WC, Troy A, Burghardt JT, Ramsey C, Lee JY, Jiang HQ, Dummer W, Shen H, Cebra JJ, Surh CD.

J Immunol. 2005 Mar 15;174(6):3158-63.

15.

Tumor immunity via homeostatic T cell proliferation: mechanistic aspects and clinical perspectives.

Baccala R, Gonzalez-Quintial R, Dummer W, Theofilopoulos AN.

Springer Semin Immunopathol. 2005 Jun;27(1):75-85. Epub 2005 Jan 22. Review.

PMID:
15666151
16.

Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin.

Vugmeyster Y, Kikuchi T, Lowes MA, Chamian F, Kagen M, Gilleaudeau P, Lee E, Howell K, Bodary S, Dummer W, Krueger JG.

Clin Immunol. 2004 Oct;113(1):38-46.

PMID:
15380528
17.

T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action.

Jullien D, Prinz JC, Langley RG, Caro I, Dummer W, Joshi A, Dedrick R, Natta P.

Dermatology. 2004;208(4):297-306. Review.

PMID:
15178911
18.

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, Bresnahan BW, Menter A; Efalizumab Study Group.

JAMA. 2003 Dec 17;290(23):3073-80. Erratum in: JAMA. 2004 Mar 3;291(9):1070.

PMID:
14679270
19.

A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.

Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, Walicke P, Dummer W, Wang X, Garovoy MR, Pariser D; Efalizumab Study Group.

N Engl J Med. 2003 Nov 20;349(21):2004-13.

20.

Subcutaneously administered efalizumab (anti-CD11a) improves signs and symptoms of moderate to severe plaque psoriasis.

Gottlieb AB, Miller B, Lowe N, Shapiro W, Hudson C, Bright R, Ling M, Magee A, McCall CO, Rist T, Dummer W, Walicke P, Bauer RJ, White M, Garovoy M.

J Cutan Med Surg. 2003 May-Jun;7(3):198-207.

PMID:
12717587
21.

Late-type allergy to Ultravist (iopromid).

Otto K, Kaempgen E, Dummer W, Broecker EB, Becker JC.

Allergy. 2003 Mar;58(3):261-2. No abstract available.

PMID:
12653805
22.

T cell homeostatic proliferation elicits effective antitumor autoimmunity.

Dummer W, Niethammer AG, Baccala R, Lawson BR, Wagner N, Reisfeld RA, Theofilopoulos AN.

J Clin Invest. 2002 Jul;110(2):185-92.

23.

Role of cyclin kinase inhibitor p21 in systemic autoimmunity.

Santiago-Raber ML, Lawson BR, Dummer W, Barnhouse M, Koundouris S, Wilson CB, Kono DH, Theofilopoulos AN.

J Immunol. 2001 Oct 1;167(7):4067-74.

24.

The role of alpha beta+ T cells and homeostatic T cell proliferation in Y-chromosome-associated murine lupus.

Lawson BR, Koundouris SI, Barnhouse M, Dummer W, Baccala R, Kono DH, Theofilopoulos AN.

J Immunol. 2001 Aug 15;167(4):2354-60.

25.

T cell homeostasis and systemic autoimmunity.

Theofilopoulos AN, Dummer W, Kono DH.

J Clin Invest. 2001 Aug;108(3):335-40. Review. No abstract available.

26.

Autologous regulation of naive T cell homeostasis within the T cell compartment.

Dummer W, Ernst B, LeRoy E, Lee D, Surh C.

J Immunol. 2001 Feb 15;166(4):2460-8.

27.

Role of self-major histocompatibility complex/peptide ligands in selection and maintenance of a diverse T cell repertoire.

Surh CD, Ernst B, Lee DS, Dummer W, LeRoy E.

Immunol Res. 2000;21(2-3):331-9. Review.

PMID:
10852134
28.

[Pemphigoid gestationis without blisters].

Ogilvie P, Trautmann A, Dummer W, Rose C, Bröcker EB, Zillikens D.

Hautarzt. 2000 Jan;51(1):25-30. German.

PMID:
10663036
29.

Differential expression of transforming growth factor beta 1 and interleukin 10 in progressing and regressing areas of primary melanoma.

Conrad CT, Ernst NR, Dummer W, Bröcker EB, Becker JC.

J Exp Clin Cancer Res. 1999 Jun;18(2):225-32.

PMID:
10464712
30.

[Model of a special consultation for patients with atopic eczema].

Dummer W, Lurz C, Rickert S, Ogilvie P, Kinkelin I, Bröcker EB.

Hautarzt. 1999 Jan;50(1):20-6. German.

PMID:
10068927
31.

Granulomatous cheilitis and Crohn's disease in a 3-year-old boy.

Dummer W, Lurz C, Jeschke R, Meissner N, Rose C, Bröcker EB.

Pediatr Dermatol. 1999 Jan-Feb;16(1):39-42.

PMID:
10027998
32.
33.

Reliability of reverse transcription-polymerase chain reaction (RT-PCR)-based assays for the detection of circulating tumour cells: a quality-assurance initiative of the EORTC Melanoma Cooperative Group.

Keilholz U, Willhauck M, Rimoldi D, Brasseur F, Dummer W, Rass K, de Vries T, Blaheta J, Voit C, Lethé B, Burchill S.

Eur J Cancer. 1998 Apr;34(5):750-3.

PMID:
9713285
35.

Occupational medicine in Chile.

Contreras GR, Dümmer W.

Int Arch Occup Environ Health. 1997;69(5):301-5. No abstract available.

PMID:
9192212
36.

Interleukin-10 production in malignant melanoma: preferential detection of IL-10-secreting tumor cells in metastatic lesions.

Dummer W, Bastian BC, Ernst N, Schänzle C, Schwaaf A, Bröcker EB.

Int J Cancer. 1996 May 29;66(5):607-10.

37.

Phase I study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene.

Stingl G, Brŏcker EB, Mertelsmann R, Wolff K, Schreiber S, Kămpgen E, Schneeberger A, Dummer W, Brennscheid U, Veelken H, Birnstiel ML, Zatloukal K, Schmidt W, Maass G, Wagner E, Baschle M, Giese M, Kempe ER, Weber HA, Voigt T.

Hum Gene Ther. 1996 Mar 1;7(4):551-63. No abstract available.

PMID:
8800750
38.

Scalp necrosis in temporal (giant cell) arteritis:implications for the dermatologic surgeon.

Dummer W, Zillikens D, Schulz A, Bröcker EB, Hamm H.

Clin Exp Dermatol. 1996 Mar;21(2):154-8.

PMID:
8759208
39.

Preoperative characterization of pigmented skin lesions by epiluminescence microscopy and high-frequency ultrasound.

Dummer W, Blaheta HJ, Bastian BC, Schenk T, Bröcker EV, Remy W.

Arch Dermatol. 1995 Mar;131(3):279-85.

PMID:
7887656
40.

Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma.

Dummer W, Becker JC, Schwaaf A, Leverkus M, Moll T, Bröcker EB.

Melanoma Res. 1995 Feb;5(1):67-8.

PMID:
7734958
41.

[Congenital poikiloderma of the verrucous type in Thomson syndrome with associated myopathy].

Blaheta HJ, Dummer W, Machetanz G, Drosner M.

Hautarzt. 1994 Jul;45(7):499-503. German.

PMID:
7928348
42.

[Videomicroscopy in differential diagnosis of skin tumors and secondary prevention of malignant melanoma].

Dummer W, Doehnel KA, Remy W.

Hautarzt. 1993 Dec;44(12):772-6. German.

PMID:
8113040
43.
44.
45.

[Psychodiagnostic characteristics of patients with functional cardiovascular disorders].

Dummer W, Hacke S, Bestvater G.

Z Gesamte Inn Med. 1984 Apr 1;39(7):138-40. German.

PMID:
6730589
46.

[Behavior therapy self control in chronic compulsive organismic defective habit development].

Dummer W.

Psychiatr Neurol Med Psychol (Leipz). 1983 Jun;35(6):357-65. German.

PMID:
6635027
47.

[Therapy-oriented relationship with hysteriform-structured patients].

Dummer W.

Z Arztl Fortbild (Jena). 1982 Mar 1;76(5):208-11. German. No abstract available.

PMID:
7080548
48.

[Practical reasons for required adjuvant psychotherapeutic treatment in internal medicine clinics].

Dummer W, Hendrik A.

Z Arztl Fortbild (Jena). 1981 Dec 15;75(24):1179-84. German. No abstract available.

PMID:
7342504
49.

[The motivation/motivatibility of functional disorder patients on an internal medical ward towards integrated psychotherapy].

Dummer W.

Z Arztl Fortbild (Jena). 1980 Sep 1;74(17):794-7. German. No abstract available.

PMID:
7445560
50.

[Concept of the management of sex deviation (methodology and current results)].

Dummer W, Burian DR.

Psychiatr Neurol Med Psychol (Leipz). 1978 Oct;30(10):599-607. German.

PMID:
733985

Supplemental Content

Loading ...
Support Center